title: Androgen dependent mammary gland virilism in rats given the selective estrogen receptor modulator LY2066948 hydrochloride.
abstract: A selective estrogen receptor modulator (SERM) is a nonsteroidal compound with tissue specific estrogen receptor (ER) agonist or antagonist activities. In animals, SERMs may produce morphologic changes in hormonally-sensitive tissues like the mammary gland. Mammary glands from female rats given the SERM LY2066948 hydrochloride (LY2066948) for 1 month at >or= 175 mg/kg had intralobular ducts and alveoli lined by multiple layers of vacuolated, hypertrophied epithelial cells, resembling in part the morphology of the normal male rat mammary gland. We hypothesized that these SERM-mediated changes represented an androgen-dependent virilism of the female rat mammary gland. To test this hypothesis, the androgen receptor antagonist flutamide was co-administered with LY2066948 (175 mg/kg) to female rats for 1 month. Female rats given SERM alone had hyperandrogenemia and the duct and alveolar changes described here. Flutamide cotreatment did not affect serum androgen levels but completely blocked the SERM-mediated mammary gland change. In the mouse, a species that does not have the sex-specific differences in the mammary gland observed in the rat, SERM treatment resulted in hyperandrogenemia but did not alter mammary gland morphology. These studies demonstrate that LY2066948 produces species-specific, androgen-dependent mammary gland virilism in the female rat.
authors.affiliation: Department of Pathology, Lilly Research Laboratories, Division of Eli Lilly and Co., Greenfield, Indiana 46140, USA. rudmanndg@lilly.com
authors.forename: Daniel G
authors.initials: DG
authors.lastname: Rudmann
authors.forename: Ilene R
authors.initials: IR
authors.lastname: Cohen
authors.forename: Michelle R
authors.initials: MR
authors.lastname: Robbins
authors.forename: David E
authors.initials: DE
authors.lastname: Coutant
authors.forename: Judith W
authors.initials: JW
authors.lastname: Henck
mesh_terms: D000726:Androgen Antagonists / Q000494:pharmacology; D000728:Androgens / Q000097:blood / Q000502:physiology; D000818:Animals; D004338:Drug Combinations; D004958:Estradiol / Q000097:blood; D005260:Female; D005485:Flutamide / Q000008:administration & dosage / Q000494:pharmacology; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008321:Mammary Glands, Animal / Q000187:drug effects* / Q000473:pathology; D051379:Mice; D009281:Naphthalenes / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D010880:Piperidines / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D051381:Rats; D011916:Rats, Inbred F344; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D012737:Sex Factors; D013045:Species Specificity; D014770:Virilism / Q000209:etiology / Q000473:pathology
chemical_list: D000726:Androgen Antagonists; D000728:Androgens; D004338:Drug Combinations; C504960:LY2066948; D009281:Naphthalenes; D010880:Piperidines; D020845:Selective Estrogen Receptor Modulators; D004958:Estradiol; D005485:Flutamide; D007986:Luteinizing Hormone